Amicus Therapeutics, Inc. logo

Amicus Therapeutics, Inc.

FOLD US

Amicus Therapeutics, Inc.United States Composite

9.77

USD
-0.27
(-2.69%)
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Bradley L. Campbell M.B.A.
Full Time Employees
484
Sector
Healthcare
Industry
Biotechnology
Address
3675 Market Street Philadelphia PA United States 19104
IPO Date
May 31, 2007
Business
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Company News

  • Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

  • Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

  • Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product

  • Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?

  • Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?

  • This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.

  • Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript

  • Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...

  • Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects Full-Year Growth

  • Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

  • Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

  • Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

  • Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

  • Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

  • Amicus Therapeutics reports mixed Q1 results; updates FY24 outlook

  • Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates

  • Amicus Therapeutics Q1 2024 Earnings Preview

  • Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

  • Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference

  • Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference